Private equity firm Carlyle Group to buy company that is developing inhaled treatment for Covid-19
The British pharmaceutical company Vectura Group, which is developing a pioneering inhaled treatment for Covid-19, has agreed a £958m takeover by Carlyle Group as it looks set to become the latest in a long line of UK businesses snapped up by private equity during the pandemic.
The board is unanimously recommending that shareholders in the London-listed company accept the offer, which represents a 32% premium to its ex-dividend closing price on the day before the deal was announced.
